• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antiinflamm Antiallergy Agents Med Chem . Post COVID-19 Syndrome Clinical Manifestations: A Systematic Review

tetano

Editor, Senior Moderator
Antiinflamm Antiallergy Agents Med Chem


. 2022 Mar 28.
doi: 10.2174/1871523021666220328115818. Online ahead of print.
Post COVID-19 Syndrome Clinical Manifestations: A Systematic Review


Muhammad Abdel-Gawad[SUP] 1 [/SUP], Mariam S Zaghloul[SUP] 2 [/SUP], Sherief Abd-Elsalam[SUP] 3 [/SUP], Mai Hashem[SUP] 4 [/SUP], Sameh A Lashen[SUP] 5 [/SUP], Aya M Mahros[SUP] 6 [/SUP], Ahmed Q Mohammed[SUP] 1 [/SUP], Amro M Hassan[SUP] 1 [/SUP], Ahmed N Bekhit[SUP] 7 [/SUP], Weam Mohammed[SUP] 8 [/SUP], Mohamed Alboraie[SUP] 9 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease-2019 (COVID-19) is a global pandemic health problem which causes a wide spectrum of clinical manifestations and considerable mortality rates. Unfortunately, recovered patients who survive COVID-19 may continue to report wide varieties of clinical manifestations of multisystem affection such as fatigue, dyspnea, myalgia, anxiety, depression, acute myocardial infarction, peripheral and pulmonary embolisms.
Objective: We aimed to assess the prevalence of post-COVID-19 manifestations.
Methods: We conducted a systematic review on post COVID-19 manifestations by searching Pubmed, Scopus, Web of Science (WOS), EBSCO, Wily, and World health organization (WHO) databases. Screening, selection, data extraction, data synthesis and quality assessment were done by two independent reviewers.
Results: Of 1,371 references, 817 references remained after duplicates, reviews; case reports, commentaries, and any article containing non-original information were removed. According to eligibility criteria for this systematic review, 12 studies were included for qualitative synthesis. The overall prevalence of post-COVID-19 manifestations ranged from 35% to 90.5%. Fatigue, dyspnea, neuropsychological disorders, and pain were the most frequent post COVID-19 symptoms.
Conclusions: This systematic review showed that 35% to 90.5% of recovered patients who survive COVID-19 continue to have wide varieties of clinical manifestations and fatigue, dyspnea, neuropsychological disorders, and pain were the most frequent post COVID-19 symptoms.

Keywords: COVID-19; Coronavirus; Post COVID; SARS-Cov-2; novel coronavirus.; pandemic; persistence post covid.
 
Back
Top Bottom